Srikripa Devarakonda analyst TRUIST

Currently out of the existing stock ratings of Srikripa Devarakonda, 152 are a BUY (92.12%), 13 are a HOLD (7.88%).

Srikripa Devarakonda

Work Performance Price Targets & Ratings Chart

Analyst Srikripa Devarakonda, currently employed at TRUIST, has had 62.18% of price targets met with an average potential upside of 43.04%, reached in 188 days on average.

Srikripa Devarakonda has documented 324 price targets and ratings displayed on 27 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MDGL, Madrigal Pharmaceuticals at 04-Nov-2026.

Wall Street Analyst Srikripa Devarakonda

Analyst best performing recommendations are on NMTR.
The best stock recommendation documented was for NMTR on 6/30/2020. The price target of $400 was fulfilled within 1 day with a profit of $41 (11.42%), with a performance score of 114.21.

Average potential price target upside

INCY yte AFMD Affimed NV CNST NMTR VSTM Verastem CYTK Cytokinetics KROS KYMR Kymera Therapeutics LLY Eli Lilly and Company ABBV AbbVie BIIB Biogen EWTX REGN Regeneron Pharmaceuticals SRRK PTGX MDGL Madrigal Pharmaceuticals NRIX TERN ABCL AMGN Amgen ARVN Arvinas BMY Bristol-Myers Squibb Company SEPN TRML ABSI Absci Corp VTRS Viatris IVA

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 03-May-2023

$117

$-3.97 (-3.28%)

$114

18 days ago
(30-Oct-2026)

52/59 (88.14%)

$-3.39 (-2.82%)

420

Hold Since 30-Oct-2026

$144

$23.03 (19.04%)

$107

18 days ago
(30-Oct-2026)

25/29 (86.21%)

$23.61 (19.61%)

655

Hold Since 20-Jan-2026

$127

$6.03 (4.98%)

$128

18 days ago
(30-Oct-2026)

13/16 (81.25%)

$6.61 (5.49%)

49

Buy Since 24-Nov-2025

$143

$22.03 (18.21%)

$139

18 days ago
(30-Oct-2026)

4/7 (57.14%)

$22.61 (18.78%)

153

Hold Since 03-Aug-2022

$127

$6.03 (4.98%)

$110

18 days ago
(30-Oct-2026)

3/4 (75%)

$6.61 (5.49%)

707

Show more analysts

Please expand the browser size to see the chart

Which stock is Srikripa Devarakonda most bullish on?

Potential upside of $315.61 has been obtained for MDGL (MADRIGAL PHARMACEUTICALS)

Which stock is Srikripa Devarakonda most reserved on?

Potential downside of -$5.97 has been obtained for INCY (YTE)

What Year was the first public recommendation made by Srikripa Devarakonda?

On 2019
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?